Citryll Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $20.8M

  • Investors
  • 6

Citryll General Information

Description

Developer of pharmaceutical drugs designed to treat autoimmune and other human diseases. The company's drugs include the formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes, enabling doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage due to sepsis.

Contact Information

Website
www.citryll.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • Kloosterstraat 9
  • Pivot Park, Gebouw OP
  • 5349 AB Oss
  • Netherlands

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Citryll Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 02-Jul-2020 $20.8M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 03-Jul-2019 0000 0000 Completed Generating Revenue
To view Citryll’s complete valuation and funding history, request access »

Citryll Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of pharmaceutical drugs designed to treat autoimmune and other human diseases. The company's drugs include the
Drug Discovery
Oss, Netherlands
19 As of 2023
000.00
0000000000 0 000.00

000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labor
0000 000000000
Cambridge, MA
000 As of 0000
00.000
000000000 00.000

000000

at. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
0000 000000000
Indianapolis, IN
0 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Citryll Competitors (52)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Blueprint Medicines Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
Apexian Pharmaceuticals Venture Capital-Backed Indianapolis, IN 0 000.00 0000000000 0 000.00
CEL-SCI Corporate Backed or Acquired Vienna, VA 00 00000 00000000 00000
Incyte Formerly VC-backed Wilmington, DE 0000 00000000000
Chemocentryx Formerly VC-backed Mountain View, CA 000 00000 000000&0 00000
You’re viewing 5 of 52 competitors. Get the full list »

Citryll Patents

Citryll Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202318703-D0 Diagnostic agent Pending 07-Dec-2023
EP-4085973-A1 Inhibition of eosinophil extracellular traps Inactive 04-May-2021 000000000 0
EP-4333981-A1 Inhibition of eosinophilic traps Pending 04-May-2021 000000000
CA-3215452-A1 Inhibition of eosinophilic traps Pending 04-May-2021 000000000
AU-2022270356-A1 Inhibition of eosinophilic traps Pending 04-May-2021 C07K16/18
To view Citryll’s complete patent history, request access »

Citryll Executive Team (8)

Name Title Board Seat Contact Info
Eduardo Bravo Chief Executive Officer
Sjoerd van Gorp Ph.D Chief Operating Officer
Renato Chirivi Ph.D Co-Founder & Chief Technology Officer
Eric Meldrum Ph.D Chairman & Chief Scientific Officer
Tim Schenk Chief Business Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Citryll Board Members (8)

Name Representing Role Since
Colin Freund Self Board Member 000 0000
Daniela Couto Ph.D BioGeneration Ventures Board Member 000 0000
Eric Meldrum Ph.D Citryll Chairman & Chief Scientific Officer 000 0000
Helmuth Van Es Ph.D Self Special Advisor CEO & Board Member 000 0000
Mariette van der Velden-Roesink Brabantse Ontwikkelings Maatschappij Board Observer 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Citryll Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Citryll Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioGeneration Ventures Venture Capital Minority 000 0000 000000 0
Laurel Venture Capital Venture Capital Minority 000 0000 000000 0
Seventure Partners Venture Capital Minority 000 0000 000000 0
Brabantse Ontwikkelings Maatschappij Venture Capital Minority 000 0000 000000 0
BrightGene Bio-Medical Technology Company Corporation Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Citryll FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »